President Trump has threatened to impose pharma tariffs to encourage investment in U.S. manufacturing, but experts say there could be unintended consequences.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.

Eli Lilly's (NYSE: LLY) share price soared during the first Trump administration ... He didn't provide details, though, on how much of an impact tariffs might have on Lilly.

Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

The Trump administration is weighing measures that would make it more expensive for pharmaceutical companies to conduct ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular diseaseLilly's established capabilities ...

The tariffs on pharmaceutical imports threatened by President Trump stand out as one key factor. Here's how those tariffs could affect Eli ... of an impact tariffs might have on Lilly.

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with ...

NEW YORK (AP) — U.S. stocks slumped on Tuesday under the weight of another jump for the price of oil. It was a return to form ...